AstraZeneca, Daiichi Sankyo push Enhertu closer to the blockbuster frontier with stomach cancer OK
Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbuster land. The FDA cleared the med for use in HER2-positive stomach cancer patients who previously received Roche’s standard-of-care Herceptin.
Source: fiercepharma.com